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A recombinant Hc fragment of botulinum neurotoxin, serotype A (rBoNTA(Hc)),has been successfully
expressed in a Mutt strain of the methylotrophic yeast
Pichia pastoris for use as a n antigen in a proposed
human vaccine. Fermentation employed glycerol
batch, glycerol-fed batch, and methanol-fed batch
phases to achieve high cell density. Induction times
were short to maximize rBoNTA(Hc) production while
minimizing proteolytic degradation. Concentration of
rBoNTA(Hc) in yeast cell lysates was generally 1-2% of
the total protein based on ELISA analysis. The Hc
fragment was purified from cell lysates using a multistep ion-exchange (IEC) chromatographic process, including SP, Q, and HS resins. The zwitterionic detergent Chaps was included in the buffer system to
combat possible interactions, such as protein-protein
or protein-DNA interactions. Following IEC was a hydrophobic interaction chromatography (HIC) polishing step, using phenyl resin. The Hc fragment was
purified to >95% purity with yields u p to 450 mglkg
cells based on ELISA and Bradford protein assay. The
purified Hc fragment of serotype A was stable, elicited
a n immune response in mice, and was protected upon
challenge with native botulinum type A neurotoxin.
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The bacteria Clostridium botulinum produces seven
serologically distinct forms (A-G) of botulinum neurotoxin which are similar in structure (1). In humans,
these neurotoxins cause acute toxicity, which results in
fatal paralysis of respiratory muscles (2). Food poisonThis article is published a s Paper No. 12994 in the Journal Series
of t h e Nebraska Agricultural Research Division, University of Nebraska, Lincoln, NE.
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ing is the familiar source of human botulism. However,
the common occurrence of infant botulism (3) and the
use of agents such as botulinum toxin in biological
warfare (4) have heightened the need for safe, inexpensive, and efficacious vaccine against all seven serotypes. If successful, a recombinant subunit vaccine
could potentially replace the current formalin-inactivated pentavalent (types A-E) toxoid vaccine as a safer
alternative.
Botulinum neurotoxin is processed from a 150-kDa
precursor to a dimer consisting of light chain (-50
kDa) and heavy chain (-100 kDa) subunits, connected
by a single disulfide bridge (5,6).The C-terminal half of
the heavy chain (the Hc fragment)2 functions in binding of the toxin (7-9) to specific receptors on peripheral
Abbreviations used: AOX1, alcohol oxidase 1; ABTS, 2,2'-azinodi-(3-ethylbenzthiazoline-6-sulfonate); BSM, basal salts medium;
Chaps, (3-[(3-cholamidopropyl)dimethylammonio]-l-propanesulfonate); CV, column volumes; DAB, diaminobenzidine; DO, dissolved
oxygen; DV, diafiltration volumes; EBA, expanded-bed absorption
chromatography; ED,,, efficacious dose to protect 50% of test animals; EDTA, ethylenediaminetetraacetic acid; ELISA, enzymelinked immunosorbent assay; FT, flowthrough fraction; H,, heavy
chain C-terminal fragment; H,, heavy chain N-terminal fragment;
HIC, hydrophobic interaction chromatography; HRP, horseradish
peroxidase; HS, high-density sulfonic acid; i.d., inner diameter; IEC,
ion-exchange chromatography; IgG, immunoglobulin G; LD,, lethal
dose to kill 50% of test animals; Mops, 3-(N-morpho1ino)propanesulfonic acid; MW, molecular weight; MWCO, molecular weight cutoff;
OD, optical density; PBS, phosphate-buffered saline; PBS-TT, phosphate-buffered saline with Tween 20 and thimerosal; PI,isoelectric
point; PMSF, phenylmethylsulfonyl fluoride; PVDF, polyvinylidene
difluoride; Q, quaternary amine; rBoNTA(H,), recombinant botulin u m neurotoxin, serotype A, heavy chain C-terminal fragment; RDB,
regeneration dextrose medium with biotin; SDS-PAGE, sodium dodecyl sulfate-polyacrylamide gel electrophoresis; S P , sulfopropyl;
T P , total protein concentration; YNB, yeast nitrogen base medium;
YPD, yeast extract peptone dextrose medium.
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cholinergic nerve cells (10). The N-terminal half of the
heavy chain (H,) forms channels in phospholipid membranes (11,12) and facilitates internalization (13) of the
light chain, a zinc-endopeptidase (14,15) which targets
nerve cells (16). While the complete holotoxin is required for biological toxicity, the Hc fragments alone
are nontoxic and antigenic (17,18) and have demonstrated the ability to elicit a protective immune response in animals challenged with native botulinum
toxin (19-22). Thus, investigations are ongoing to develop a multivalent vaccine against botulism using the
Hc fragments of C. botulinum neurotoxin (21-26). A
recombinant C fragment botulinum neurotoxin produced in Escherichia coli has been shown to elicit an
immune response in mice (19). Previously, recombinant Hc fragment of serotypes B and F have been
expressed in the methylotrophic yeast Pichia pastoris and purified to homogeneity (21,27). This paper
similarly describes the successful expression, purification development, and pilot-scale purification of the
Hc fragment of botulinum neurotoxin serotype A
(rBoNTA(Hc))from P. pastoris.
Methylotrophic yeast can utilize methanol for
growth and energy (28-30) and P.pastoris has been
used extensively as a host system for the expression of
foreign genes (31-39). Intracellular expression of a
synthetic gene coding the Hc fragment of rBoNTA is
possible by integration into the A O X l gene of the Mut'
strain (39 - 43) of P. pastoris. Switching the cell's carbon source from glycerol to methanol activates the
A O X l promoter (44-46) and induces production of
rBoNTA(Hc) in Pichia. A complete discussion of a
model describing rBoNTA(Hc) production in P. pastoris
is described elsewhere (47).

TABLE 1
Methanol Feed Profile during 60-L Fermentation
Time, h

Methanol feed rate, mL L-' h-'

Fermentation. Frozen stock seed culture of P.pastoris was grown a t 30°C to an A,,, of five to six in shake
flasks containing 200 ml of YNB plus phosphate medium (13.4 glL yeast nitrogen base without amino acids, 20 glL glycerol, 0.4 mglL biotin, in 100 mM potassium phosphate buffer, pH 6.0). The shake flask
culture was used to inoculate a 5-L BioFlo I11 seed
fermentor (New Brunswick Scientific, Edison, NJ) containing 4% glycerol in 4 L basal-salt medium (BSM)
(48) plus 2 mLlL of PTM, trace mineral salts. Dissolved
oxygen (DO) was maintained a t 40%, and pH was controlled a t 5 using 30% ammonium hydroxide. The culture was grown to an OD of 35 a t 600 nm. Large-scale
fermentation was conducted with a starting volume of
45 L of BSM plus 2 ml/L PTM, trace mineral salts, in
a 60-L New Brunswick Scientific MPP-80 fermentor.
The 60-L fermentor was inoculated with 3.5 L of the
seed inoculum. The culture was grown to an OD of 57
a t 600 nm, a t which time the DO spiked indicating
glycerol exhaustion. A 50% (wlv) glycerol solution was
then fed into the fermentor a t a rate of 20.2 ml L-' h-'
for 60 min. The glycerol feed was then linearly reduced
to zero over the next 3 h. After 1.5 h, when a glycerol
feed rate of 10.0 ml L-' h-' was obtained, the methanol
feed was started, beginning the induction phase. A
solution
of 100% methanol plus 1.2% PTM, was added
MATERIALS AND METHODS
a t a rate of 5.0 ml L-' h-'. The methanol feed rate was
Expression vector construction and cell culture. A increased over time to a final induction time of 9 h,
recombinant strain of P. pastoris [GS115-(hid)] was according to the profile in Table 1. The final volume of
transformed with the integrative plasmid PHIL-D4 (a the broth was 55 L with an OD of 165. Cells were
gift from the Phillips Petroleum Co., Bartlesville, OK) harvested by centrifugation using a Westfalia SA-7
containing a synthetic gene encoding the putative frag- disk stack centrifuge (Centrico, Inc., Northvale, NJ)
ment C region (heavy chain fragment) of botulinum and then stored frozen a t -40°C until use.
toxin type A. Integration was performed with an SstICell disruption. Frozen cells were suspended into
digested construct that targets integration by single cold (4°C) lysis buffer (50 mM Mops, 0.25% Chaps, 50
crossover in the chromosomal A O X l locus of P. pastoris mM NaC1, 5 mM EDTA, 2 mM PMSF, pH 7.5) a t 200
such that the gene remains intact a s the Mut' pheno- glL and disrupted a t 20,000 psig with five passes
type. Transformants were selected for conversion to through a Microfluidics M- 11OEH homogenizer (MiHis' selection on RDB medium (48) containing 20 g/L crofluidics, Corp., Newton, MA) equipped with a heat
agar and then further selected for high copy number by exchanger for cooling. The lysate was centrifuged
their ability to grow on YPD medium (48) containing (Beckman, Palo Alto, CA) a t 12,000g for 25 min to
the antibiotic G418. Seed cultures of the selected trans- pellet cell debris. Lysate supernatants were diluted
formant, designated as BAC-C-09056-A9 [BoNTA(Hc)/ with cold lysis buffer (without PMSF) to a total protein
PHIL-D4], were prepared in YPD medium containing concentration of approximately 5 mg/ml and then filtered through a 0.5-pm filter (Pall, Port Washington,
15% glycerol and stored a t -80°C.
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NY) in preparation for loading onto the SP-Sepharose
column, the first chromatography step. For lab-scale
evaluations, cells were broken with six 1-min cycles in
a bead blender containing 75-80 g cells, 160 ml beads,
and 175 ml of lysis buffer. Following centrifugation,
the supernatant was diluted with lysis buffer to a
protein concentration of approximately 5 mglml for
loading.
Purification of rBoNTA (H,) fragment. A 10.0-cm
inner diameter (i.d.) BPG chromatography column
(Pharmacia Biotech, Uppsala, Sweden), containing 2.0
L of SP-Sepharose Fast Flow cation-exchange resin
(Pharmacia), was used in the first purification step.
The separation was performed by first equilibrating
the resin with 12 column vol (CV) of buffer (50 mM
Mops, 50 mM NaC1, 0.25% Chaps, 5 mM EDTA, pH
7.5) a t 500 cmlh. The column was loaded with 6.6 L of
diluted cell lysate a t 5.9 mglml total protein concentration, a t 100 cmlh. Protein load was 19.5 mglml-resin.
The column and buffers were maintained a t ambient
temperature, and the sample was kept on ice during
loading. The column was washed with 2.5 CV of equilibration buffer a t 100 cmlh, followed by 7.5 CV a t 500
cmlh. Product was desorbed by step elution with 6 CV
of 300 mM NaCl in equilibration buffer (without
EDTA). The column was eluted with 1 M NaCl in
buffer and then cleaned with a mixture of 1 M NaOH
and 1 M NaC1. The fraction obtained from the SP
column was diafiltered a t 4°C against 5 vol of 50 mM
Mops, 0.25% Chaps, pH 7.5, using 20 f t 2 of 5,000
MWCO PES sheet membrane in a Septaport module
(NC SRT, Cary, NC) to decrease the sample conductivity in preparation for the second step.
The second chromatography step was negative purification using Q-Sepharose Fast Flow anion-exchange
resin (Pharmacia).A 10.0-cm i.d. BPG column containing 1.4 L of resin was equilibrated with 10 CV of buffer
(50 mM Mops, 0.25% Chaps, pH 7.5) a t 450 cmlh prior
to loading the diafiltered S P product pool. The column
and buffers were maintained a t ambient temperature,
and the sample was kept on ice during loading. After
loading was complete, the column was washed with 6
CV of equilibration buffer. The flowthrough fraction
containing the rBoNTA(H,) product was collected.
Bound proteins were eluted with a step to 1 M NaCl in
Mops buffer. The column was cleaned with a mixture of
1 M NaOH and 1 M NaC1. The Q product fraction was
adjusted to 50 mM NaCl in preparation for the third
step.
The third chromatography column was a 10.0-cm i.d.
column containing 1 L of Poros HS-50 (PE Biosystems,
Framingham, MA). The column was equilibrated a t
750 cmlh with 50 mM Mops, 0.05% Chaps, 75 mM
NaC1, pH 7.5 for 10 CV. The Q product was applied a t
750 cmlh. The column and buffers were maintained a t
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ambient temperature, and the sample was kept on ice
during loading. A step to 180 mM NaCl in buffer for 8
CV eluted the product. The column was flushed with 1
M NaCl and then cleaned with a mixture of 1 M NaOH
and 1 M NaC1.
In the final chromatography step, the HS product
fraction was adjusted to 2.6 M NaCl and applied to a
6.0-cm i.d. column containing 700 ml of Phenyl 650C
hydrophobic interaction (HIC) resin (TosoHaas, Montgomeryville, PA). The column was preequilibrated with
10 CV of high-ionic-strength buffer (2.6 M NaCl in 50
mM sodium phosphate, pH 7.5) a t 500 crnlh. The column and buffers were maintained a t ambient temperature, and the sample was kept on ice during loading.
After loading was complete, the column was washed
with 10 CV of equilibration buffer, and then product
was eluted with a step to 50 mM NaCl in phosphate
buffer and held for 6 CV. The column was cleaned with
a mixture of 250 mM NaOH and 250 mM NaC1.
The HIC product fraction was diafiltered using a
10,000 MWCO, 3-ft2spiral-wound cartridge (Millipore,
Bedford, MA) against 20 mM sodium phosphate buffer,
pH 7.5, to remove residual salt. The product was concentrated to a final concentration of 0.2 mglmL, aliquotted, and frozen a t -70°C for storage.
Total protein analysis. Total protein concentration
of samples was determined using the Bio-Rad protein
assay, based on the method of Bradford (49) (Bio-Rad
Laboratories, Hercules, CA), using bovine serum albumin (Pierce Chemical Co., Rockford, IL) as the reference standard.
SDS-PAGE and Western blot analysis. Samples
taken a t various stages of purification were analyzed
by SDS-PAGE using 4 -20% gradient acrylamide gels
(Novex, San Diego, CA) based on the method described
by Laemmli (50). Samples were mixed with SDSPAGE sample buffer containing 0-mercaptoethanol as
a reducing agent. Gels were stained with either Coomassie brilliant blue (Sigma Chemical Co., St. Louis,
MO) or silver (Pharmacia). For Western blot analysis,
the gels were transferred to a PVDF membrane (BioRad) a t 100 V for 1.25 h. Blots were incubated in 5%
nonfat dry milk for 1 h a t ambient temperature,
washed with 0.05% Tween 20 in phosphate-buffered
saline, and then treated with the primary antibody, a
rabbit polyclonal anti-BoNTA(H,) in PBS containing
5% goat serum for 1 h a t ambient temperature. Blots
were again washed and then incubated with goat antirabbit IgG conjugated to horseradish peroxidase (HRP)
(Kirkegaard & Perry Laboratories, Inc. (KPL), Gaithersburg, MD) diluted 115000 in PBS containing 5% goat
serum for 1 h. Immunoreactive proteins were visualized by metal-enhanced DAB substrate (Pierce).
Enzyme-linked immunosorbent assay (ELISA).
Samples taken a t various stages of purification were
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TABLE 2
Storage Time a n d Cell Breakage of Pichia pastoris Cells, Lot No. AR-FPP-003-G
Cell Age

Percentage of disruption

Run name

Weeks

Months

Pass 1

Pass 2

Pass 3

Pass 4

Pass 5

Lysate
TP Concn
(mglml)

003G
PPP-003
SP-Q
PPP-004
PPP-004.1
PPP-005

2
17
19
30
30
34

0.5
4.0
4.4
7.0
7.0
7.9

n.d."
44%
n.d.
n.d.
42%
41%

n.d.
74%
n.d.
n.d.
51%
54%

87%
83%
n.d.
67%
58%
56%

n.d.
85%
90%
84%
72%
66%

94%
91%
96%
n.d.
81%
66%

14.2
12.9
8.8
8.7
7.8
5.9

TP
released
(mglg cells)

90
86
75
62
60
50

" n.d., not determined.

analyzed by a sandwich ELISA. Ninety-six-well microtiter plates were coated with a mouse anti-BoNTA(H,)
monoclonal capture antibody (0.5 pgiml) a t 4°C overnight. Plates were washed with carbonate buffer (100
mM sodium carbonatelbicarbonate, pH 9.6) plus 0.05%
(wlv) Tween 20 and then blocked with 5% nonfat dry
milk in carbonate buffer for 2- 4 h a t 37°C. Plates were
again washed. Samples were diluted with 5% nonfat
dry milk plus 0.05% Chaps in carbonate buffer and
then added to wells and incubated a t 37°C for
1.5 h. Plates were washed, and 2 pgiml horse antiBoNTA(H,) polyclonal antibody was added to wells
and incubated a t 37°C for 1 h. Plates were washed with
phosphate-buffered saline plus 0.05% Tween 20 and
0.01% thimerosal (PBS-TT). Plates were then incubated with 1 pgiml goat anti-horse IgG(H+L) horseradish peroxidase-labeled antibody (KPL) a t 37°C for
1 h. Plates were washed with the PBS-TT solution and
incubated with ABTS peroxidase substrate solution
(KPL) a t 37°C until darkest standard was a t 2 AU. A
2% oxalic acid solution was added to stop color development, and color was measured using the MRX plate
reader with Revelation software (Dynex Technologies,
Inc., Chantilly, VA). Samples were quantified against a
standard curve prepared from purified rBoNTA(H,)
fragment.
Dose response. Ten mice per group were vaccinated
with purified rBoNTA(H,). Seven groups were injected
with 11 ng per mouse, 33 ng per mouse, 100 ng per
mouse, 300 ng per mouse, 900 ng per mouse, 2.7 pg per
mouse, or 8.1 pg per mouse. The control group of animals received diluent only (0.2% Alhydrogel in 0.8%
saline with 0.8% benzyl alcohol as a preservative).
Vaccines were administered intramuscularly in the
hind leg muscle in a volume of 100 p1. Animals were
challenged a t 2 1 days postvaccination with l o 3 mouse
LD5,/ml botulinum type A toxin diluted in gel-phosphate buffer (0.4% dibasic phosphate with 0.2% gelatin), delivered intraperitoneally. Mice were observed
daily for 5 days postchallenge.

Amino-terminal sequence analysis. The amino-terminal sequence of recombinant rBoNTA(H,) fragment
was determined by automated Edman degradation
performed on a Procise Model 49 1-HT amino acid sequencer (PE Biosystems).
RESULTS AND DISCUSSION

Pilot-scale fermentation and purification processes
and supporting lab-scale development work are presented for isolating rBoNTA(H,) from P. pastoris. During fermentation, the rBoNTA(H,) content in cells increases with induction time, until a plateau is reached,
after which the rBoNTA(H,) concentration decreases
quickly (47). The ratio of intracellular expressed
rBoNTA(H,) to total protein drops after 10-1 2 h of methanol induction, resulting in a shorter induction phase
than is typical for expression in Pichia. Cells were
harvested from the fermentor after 9 h of methanol
feeding to maximize yield of the rBoNTA(H,) product.
Expression of rBoNTA(H,) in Pichia was successful in
both 5- and 60-L fermentations, and whole cells were
stored a t -30°C from time of harvest until use. A 20%
suspension of frozen cells stored less than 6 months
and disrupted a t 20,000 psig resulted in 90-95% cell
breakage based on microscopic inspection. Cell lysis
typically yielded a t least 70 mg total protein (TP) per
gram of wet cell weight after short-term storage. Several runs (lab and pilot scale) were performed using the
same lot of cells over an 8-month period. Analysis of
cell lysate protein concentration and percentage of
breakage of cells revealed that long-term storage of
cells severely affects protein yield and lysis efficiency
(Table 2). This is likely due to dehydration of cells and
resultant precipitation of protein during frozen storage. Ideally, the cells should be processed immediately
for highest rBoNTA(H,) yield, but at maximum, frozen
cells should be processed within 3 to 4 months of harvest.
Purification of rBoNTA (Hc) fragment. The purification scheme described herein has repeatedly pro-
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duced product of 95% purity based on silver-stained
SDS-PAGE and 98% purity based on Coomassiestained SDS-PAGE, with final product yields ranging
from 100 to 450 mglkg of wet cell mass based on Bradford protein assay. Product stability increased with
subsequent processing steps and cold storage of the
Poros HS fraction pool (post-third step) proved acceptable for short periods. Expedient processing of the antigen after cell lysis was found imperative to product
integrity. Initially, there was significant loss of product
to the pellet upon centrifugation, the flowthrough fraction of the S column, and the bound fraction on the Q
column. These observations were opposite to the expected chromatographic behavior of the protein based
on its basic isoelectric point (PI
9.3). Product loss was
ascribed to suspected protein-protein andlor proteinDNA interactions occurring between the positively
charged rBoNTA(H,) fragment and negatively charged
cell components; therefore, zwittergent 3-10 and 3-12
detergents (Calbiochem, La Jolla, CA) and the zwitterionic detergent Chaps (Calbiochem) were tested for
their ability to break up these interactions. All were
successful in combating the unwanted interactions. Of
the three, Chaps was reported to be less denaturing to
protein, so it was selected as a buffer additive.
During initial screening, several resins of SP functionality were tested, including Streamline (Pharmacia) expanded bed absorption chromatography (EBA).
EBA however was not selected as a capture step for
this protein because much of the product was lost to
the flowthrough under the conditions tested (pH
screening from 5 to 7 using various buffers and NaCl
concentrations). Therefore, conventional chromatography was employed for capture. Initially, Poros HS resin
(PE Biosystems) was used in the first step and the
rBoNTA(H,) product was eluted with a gradient. This
resulted in an elution profile of two fused peaks. The
two peaks were fractionated and processed separately
and determined there was no difference in the final
product recovered from each peak. Product was present
in both of the peaks, and resolution of these two peaks
was not deemed necessary since contaminants were
removed downstream. To decrease cost, the process
was changed to use SP-Sepharose resin (Pharmacia)
with step elution of the product. The SP-Sepharose
resin also removed a contaminating 50-kDa band, nonreactive in Western blots.
Loading study. A loading study based on total protein loaded per milliliter of resin was performed using
SP-Sepharose FF resin. The SP-Sepharose resin was
evaluated for protein load capacity, as determined
by breakthrough of rBoNTA(H,) product in the
flowthrough (FT) fraction. A total of 50 mglml-resin
was loaded onto a 108-ml column (2.7 X 19 cm) at 100
c d h and fractions were collected, each of which repre-
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FIG. 1. Coomassie-stained SDS-PAGE gel of the process fractions.
Lane 1, S P product; lane 2, Q product; lane 3, HS product; lane 4 ,
final product; lane 5, MW standards, from bottom, 6, 16, 30, 36, 50,
64, 98, and 250 kDa. Lane W, a Western blot of the product fraction
probed with polyclonal rabbit anti-rBoNTA(H,) antibody and detected by HRP-DAB.

sented approximately 2.5 mglml-resin loaded. The running buffer was 50 mM Mops, 50 mM NaC1, 0.25%
Chaps, pH 7.5, and column was eluted with a linear
gradient to 250 mM. Product that eluted from the SP
column was further processed using Q, HS, and HIC
resins; final yield was 29.1 mg TP (375 mglkg cells).
The cutoff for minimal loss of product to FT was 20
mglml-resin; however, at 50 mglml-resin loss was less
than 10%. A positive Western signal was detected in all
flowthrough fractions, and immunoreactive bands at
50, 36, and 17 kDa were detected, indicating degradation. Under these conditions, 4% of the total protein
loaded was recovered in the elution peak, and the product pool was approximately 25% rBoNTA(H,) fragment
based on SDS-PAGE.
SP cation-exchange chromatography efficiently captured the rBoNTA(H,) fragment and with a large proportion of contaminating proteins flowing through the
column. Based on an evaluation of flow velocity and
protein concentration of the load material, maximum
capture of product was achieved when total protein
concentration was less than 5 mglml and load velocity
was relatively slow at 100 c d h . At pilot scale, the
rBoNTA(H,) fragment was detected in the flowthrough
fraction at less than 5% of the load based on ELISA.
The SP product fraction contained approximately 25%
Hc fragment based on ELISA and SDS-PAGE (Fig. 1,
lane 1).
The second chromatography step was a negative purification step using Q-Sepharose FF (Pharmacia). The
rBoNTA(H,) fragment is a basic protein with a p I of
9.3 and is present in the column flowthrough. This step
removed many contaminants, some possibly associated
with the product (Fig. 1, lane 2). Bound contaminants
were eluted from the Q resin with 1 M NaCl for analysis. A small portion of product was present in the Q
elution fraction, determined less than 5%.

398

POTTER ET AL

The third chromatography step utilized a Poros HS
column, which removes a prominent higher molecular
weight band from the product, as well as other less
discernible bands. Analysis of the HS fractions by
SDS-PAGE showed approximately 90% purity after
this step. The product band (50 kDa) which is immunoreactive by Western blot coelutes with a 17-kDa
protein (Fig. 1, lane 3).
Addition of Chaps to buffers. Due to high losses of
product to the flowthrough fraction during initial capture from lysate supernatants, it was speculated
that there was an interaction occurring between the
rBoNTA(H,) and other proteins or nucleic acid. As
mentioned previously, zwitterionic detergents were
tested for their effect, and Chaps proved both to be
nondenaturing and to have prevented product loss.
Thus, Chaps facilitated the increased release of product from the cells and complete capture by the cationexchange resin. Optimization of the capture step was
performed using 0.05% Chaps in lysis and running
buffers and included evaluation of lysate protein concentration and load velocity, both a t 10 mglml resin on
a 1.6-ml Poros HS column. There was no difference
when 1 or 5 mglml lysate protein concentration was
loaded onto the column a t 10 mglml-resin, 400 crdh
load velocity, when comparing loss to flowthrough on
the HS column. Both resulted in 17-18% product loss
based on ELISA. Load velocities of 100, 200, 300, and
400 cmlh were tested and lower load velocities resulted
in increased product yield. Therefore, a load velocity of
100 cmlh was selected.
Chaps concentration was varied in the lysis buffer to
see if increasing the Chaps would facilitate release of
higher rBoNTA(H,) levels from cells into the supernatant fraction. Cells were lysed a t small scale (1-ml bead
beater samples) in Mops lysis buffer a t 0.05, 0.1, 0.2,
and 0.3% Chaps and supernatants were analyzed by
ELISA. Varying concentrations of Chaps were added to
the lysis and running buffers. The effect of Chaps on
product capture was evaluated using a 1.6-ml Poros HS
column, loading a t 10 mglml-resin, and a load velocity
of 100 cmlh. The flowthrough fractions were tested for
rBoNTA(H,) by ELISA and final yield calculated based
on total protein. Results are summarized in Table 3.
To confirm that the increase in percentage of
rBoNTA(H,) released from cells was a real phenomenon and not due to enhanced antibody-antigen affinity
(detected by ELISA) due to Chaps interference, two
complete purification runs were done a t lab scale starting with a 100-ml HS column to capture a t 10 mglmlresin, comparing 0.25% Chaps and 0.05% Chaps. Yield
was almost doubled using the higher Chaps to break
cells and capture rBoNTA(H,) from supernatant, confirming that increased Chaps concentrations did facilitate release of more rBoNTA(H,) from cells during

TABLE 3
Effect of the Zwitterionic Detergent Chaps
on Capture and Yield of rBoNTA(H,)

Concentration
of Chaps (%)
0.05
0.10
0.20
0.25
0.30

rBoNTA(Hc)
to total protein
ratioa (%)

rBoNTA(Hc)
in flowthrough
fraction (%)

Final yield
of rBoNTA(Hc)

2.3
4.5
4.9

17

7 1 mglkg cells

8

n.d.

n.d.

6.0

3

n.d.b
n.d.
123 mglkg cells
n.d.

2

" Released in supernatant

* n.d., not determined.

lysis. Based on these results, 0.25% Chaps was selected.
Poros HS-50 resin was compared to Pharmacia SPSepharose FF resin for the capture step using 100-ml
columns, and Poros HQ-50 was compared to Q-Sepharose F F for the second step (80-ml columns). Two runs
were done, both using 0.25% Chaps throughout steps 1
and 2 in the process and then using 0.05% Chaps for
step 3 (Poros HS, 28 ml), followed by HIC (no Chaps) as
step 4. The purpose of using 0.25% Chaps throughout
step 2 was to see if it would decrease the amount of
rBoNTA(H,) lost to the Q elution fraction. At pH 7.5
rBoNTA(H,) would have an expected net positive
charge based on its isoelectric point of 9.3, and should
flow through the positively charged Q column. However, probable interactions with negatively charged
molecules (in the absence of Chaps) were causing Q
"binding." The Pharmacia resins yielded 191 mglkg of
rBoNTA(H,) versus 132 mglkg with the Poros resins,
and final product was of comparable purity. Therefore,
the Pharmacia resins were exchanged for Poros in the
first two steps in the process. Poros HS resin was still
used in the third step, to take advantage of different
selectivity between the two cation-exchange resins.
PI 7 contaminating protein. A contaminating band
of approximately 17 kDa was detected in the product
fraction by SDS-PAGE from the initial stages of processing and was present upon cell lysis. It was very
difficult to separate P17 from the BoNT-A(H,) fragment, indicating that it had similar chromatographic
properties. Running various NaCl gradients on HS
chromatography resulted in elution of P17 in the front
shoulder of the rBoNTA(H,) peak, but the two were not
able to be resolved.
Diafiltra tion through 30K membrane. rBoNTA(H,)
product containing P17 was diafiltered using a 30,000
MWCO filter to see if the P17 would pass through
while retaining the rBoNTA(H,) product. Figure 2
shows the results of permeate and retentate samples
taken a t various times during the diafiltration process.
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FIG. 2. Silver-stained SDS-PAGE gel where the HS product was diafiltered to test for removal of PI7 through a 30-kDa MWCO membrane.
Lane 1, permeate a t 1 diafiltration volume (DV); lane 2, retentate a t 1 DV; lane 3, MW standards, from bottom, 4, 6, 16, 30, 36, 50, 64, 98,
and 250 kDa; lane 4, permeate a t 2 DV; lane 5, retentate a t 2 DV; lane 6, permeate a t 3 DV; lane 7, retentate a t 3 DV; lane 8, permeate a t
4 DV; lane 9 , retentate a t 4 DV.

The P17 protein was not readily separated, though
over time the intensity of the P 17 band decreases relative to the product band. P 17 that might have passed
through the membrane was not detectable by silverstained SDS-PAGE. There is some, albeit minimal,
loss of the product through the membrane as well. The
disadvantage of polishing the product to purity by this
method was that at higher diafiltration volumes, precipitation of the protein began to occur. Alternately, a
fourth chromatography step (HIC) was implemented.
Hydrophobic interaction chromatography. P henyl
HIC was used as a polishing step to separate the 17kDa protein from the 50-kDa product (Fig. 1, lane 4).
Ammonium sulfate and sodium sulfate were both
tested and resulted in two resolved peaks at pH 8.5,

but due to the volatility of ammonium sulfate at this
pH, ammonium sulfate gradients were not reproducible from run to run. A nonvolatile alternative, sodium
sulfate, worked well at the high pH; however, clumping
and slow dissolution of the salt when mixing buffers
was problematic, especially at pilot scale. Sodium chloride was therefore investigated and found to be better
a t binding the product while selectively excluding P 17.
Sodium chloride concentrations between 1 and 3 M
were tested in 0.2 M increments to find the optimum
binding characteristics. At lower NaCl concentrations,
some product was lost to the flowthrough, yet a t higher
concentrations P 17 also bound. Optimum concentration was found to be between 2.3 and 2.7 M NaC1. By
excluding P 17 in the flowthrough fraction, the product

TABLE 4
Pilot Run Purification Table, Lot PPP-005
Protein Concn
(mglml)"

Volume
(ml)

Total protein
(mg)

rBoNTA(Hc)
(mg)

rBoNTA(Hc)

Purification step
Lysate
SP-Sepharose pool
Diafiltered for Q
Q-Sepharose pool
Poros HS pool
HIC phenyl pool
Final product pool

5.87
0.294
0.200
0.055
0.103
0.090
0.210

6600
8650
7650
16800
3675
2350
820

38742
2543
1530
924
379
212
180

37 1
588

0.96
23

1
24

319

35
90

37
94

197

99

103

" Based on Bradford protein assay, quantitated from a BSA standard curve.
Mass balance values are affected by a n approximate 30% error associated with the ELISA assay.
' Based on ELISA and/or SDS-PAGE gel analysis.

(%)

C

Fold
purification
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could be eluted in a single step to phosphate. Using
phosphate as the buffering agent, the eluted product
needed only to be concentrated and filtered prior to
vialing.
A summary of the recovery process run at pilot scale
is presented in Table 4 and Fig. 1. The final yield of
pure rBoNTA(Hc)from 785 g of wet cell mass was 172
mg (219 mglkg). The first SP step was efficient at
capturing 95% of rBoNTA(Hc) fragment from cell lysates. As mentioned previously, long-term storage of
frozen cells affects yield upon cell lysis. Hence, final
rBoNTA(Hc) yield is subsequently affected, compared
with a maximum yield of 450 mg of rBoNTA(Hc) per
kilogram of wet cell weight (Bradford protein assay)
when using fresh cells.
Amino-terminal sequence analysis. Amino-terminal sequencing indicated that the N-terminus of
the purified product was 65% intact H,N-MRLLSTFTEYIK (the expected N-terminal sequence of
rBoNTA(Hc)) and 35% H,N-STFTEYIKNI, a species
missing the first four amino acids. The N-terminal
sequence of P17 taken off PVDF membrane was H,NXVNXQTXKRKDF, which does not match any internal
sequence of rBoNTA(Hc). A sequence match for P 17
was not found in the database (GenBank) for any
catalogued Pichia protein, though homology to a
chymotrypsin-like protease of Streptomyces sp. was
suggested.
Final product stability. Several agents were tested
as possible storage buffers, including citrate, ascorbate, succinate, phosphate, and glycine. Product, when
stored frozen inthesk buffers ranging in pH from 5 to
10, did not display much banding difference on SDSPAGE over time (Fig. 3). The purified protein remained
stable when frozen a t -20°C in sodium phosphate, pH
7.5, buffer. After 4 months, there was no difference in
the banding pattern of the product. Stability of the
purified antigen did not appear to be significantly dependent upon storage buffer conditions.
The mouse model. An in vivo potency assay was
necessary to evaluate the effects of manufacture, for-

TABLE 5
rBoNTA(H,) Challenge Data: Survivors per 10 Mice
Immunization
dose
(pglmouse)

Reference
Lot 55-153-C
(EDSo= 0.04961
pglmouse)

cGMP
Lot 022399
(EDSo= 0.05272
pglmouse)

8.1
2.7
0.90
0.30
0.10
0.033
0.01 1

10110
10110
10110
10110
8/10
2/10
1/10

10110
10110
10110
8110
6110
4110
2110

mulation, storage, and stability of botulinum Hc fragments as vaccine candidates. Since the recombinant
product has no catalytic activity, it was assayed by
testing the ability of the protein to elicit protective
antibodies in mice, and the efficacious dose was (ED,,)
determined for each batch of rBoNTA(Hc)vaccine. The
dose-response ED,, curve was reproducible and sensitive to slight changes in potency. Vaccination with one
0.10-pg dose of rBoNTA(Hc)fragment afforded protection from challenge in 60% of the mice (Table 5), 0.30
pg protected 80% of the mice, and 0.90 pg protected
100% of mice challenged. The nontoxic H, fragment
elicits an immune response in mice sufficient to provide protection when challenged with native toxin.
CONCLUSION

Developing a large-scale purification process for the
rBoNTA(Hc)was somewhat problematic due to its basic isoelectric point and propensity to interact with
negatively charged cell constituents, but incorporating
Chaps into the lysis and running buffers alleviated this
problem. Using aged cells in later pilot runs resulted in
low yield compared to working with fresh cells on lab
scale. Information regarding process validation was
gained from this project, such a s limits on storage of
cells and protein stability issues. Despite the laborious
purification process, th; final pure ~BONTA(H,)product is stable, elicits protection in mice against native
botulinum type A toxin, and is a good candidate for
inclusion in a multivalent recombinant subunit vaccine.
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